Supreme Court Declines Apotex Appeal Of Plavix Suit

By Richard Vanderford

Law360, New York (November 02, 2009, 5:37 PM ET) -- Apotex Inc.'s legal dispute with Sanofi-Aventis over blood-thinning drug Plavix has hit a dead end, with the U.S. Supreme Court refusing to hear the generic-drug maker's arguments over whether substances produced by so-called obvious-to-try experiments should be patentable.

The Supreme Court denied Apotex's petition for a writ of certiorari Monday, the last in a string of decisions against Apotex in the dispute.

Sanofi sued Apotex in 2002, shortly after the generics maker filed an abbreviated new drug application to market clopidogrel bisulfate, sold by Sanofi and...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles